Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1328)	3/18/2008 12:43:01 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

reminders to self, if I get a chance to do any homework review carefully the DRUG DISCOVERY PLATFORMS section, that is the sort of googling I enjoy anyway. ----------------------------- Lorcaserin--5-HT2C receptor agonist, that is on the Merck not interested list ------------- The Circadian section is all over the map, a fantasy shopping list too. I see they're not interested in persuing partnerships in melatonin modulators or antihistamines. Well, there is no money in that (but those are the only things that work for me). ---------------------------- ANA598--NS5B polymerase inhibitor NS5B is not listed at all, but NS5A is (see below) Merck interested ANTIVIRALS – HCV Areas of Interest: • Protease inhibitors – 1st generation - Phase II or later – 2nd generation – active against genotypes 1, 2, and 3, and key mutants with preclinical safety data and PK suggestive of b.i.d. dosing • Nucleoside inhibitors • Non-nucleoside inhibitors in Phase II/II • Small-molecule inhibitors of HCV helicase • NS5A inhibitors with proven mechanism of action • HCV viral entry inhibitors • Orally active TLR agonists • Cyclophillin or cyclosporin analogues • Novel mechanism agents I should go over to Dew's thread at that other place and review HCV. Or I'll install this World of Warcraft free 14 day demo, heh.